creat altern dose leader
initi ntrb buy pt
initi coverag nutriband inc emerg drug deliveri
compani buy rate price target
januari ep project discount annual rate
believ burgeon pipelin medic solut emerg
consum offer nutriband pois becom key player
transderm patch market abil regist strong top line
bottom line growth defent abus deterr fentanyl patch roll
solut type diabet new consum market
come on-line although conserv investor believ risk/
reward ntrb compel
nutriband inc emerg leader transderm
patch market medic consum applic
recent acquisit lead player therapeut
ad technolog formula expertis expand
fentanyl transderm patch type diabet
market among other offer third parti test
servic compani also partner best
choic inc distribut transderm patch
consum market asia
emerg transderm player found nutribrand
focus becom lead global player medic
transderm patch grow market effect
easier take deliveri system believ transderm patch
increasingli futur medic deliveri
acquisit bring fentanyl patch solut defent track
roll-out third parti test servic manufactur
capac formul mix
defent near term catalyst patent pend fentanyl
patch first offer abus deterr formul
believ defent crucial success billion fentanyl
roll consum patch asia may nutriband
sign year minimum million distribut agreement
best choic inc consum transderm patch asia
begin regist revenu
carmel bioscienc acquisit step altern
dose market announc septemb carmel lead
liquid dosag player alreadi approv fda drug
view project conserv possibl product
driven compani exclud carmel deal new
consum agreement conserv manag
project impact defent roll-out said defent delay
cancel impact nutriband would highli materi
view price target balanc risk/reward
ntrb price target translat ep discount
annual rate visibl defent becom clearer
expect discount declin view risk/reward compel
aggress investor
initi coverag nutriband inc ntrb craft altern
initi coverag nutriband inc ntrb nutriband
emerg drug deliveri compani emphasi transderm patch
technolog buy rate price target januari
ep discount annual rate believ roll-out
defent abus deterr patch technolog deliveri fentanyl
grow consum third parti servic platform near term
longer term transderm patch solut medicin deliveri
type diabet opioid follicl simul hormon key
ailment nutriband aris leader transderm patch space
recent announc acquisit liquid drug deliveri system player
carmel bioscienc inc complet key altern drug deliveri player
view project strike pragmat balanc product driven
compani assum new drug rollout besid defent aggress
postur term fund new rx product incorpor potenti
accret carmel bioscienc acquisit project oper margin
manag confid achiev assum
compani switch full tax payer current share count
ntrb share dilut share outstand overal share
count said project roll-out defent food
drug administr fda approv defent captur
immedi materi approxim market share
believ creat conserv case incorpor fda approv
time roll-out defent guarante drug launch time
market share gain project recommend ntrb
conserv investor said believ risk/reward appropri
initi coverag ntrb buy rate price target
emerg transderm patch player found dublin ireland
entrepreneur ceo gareth sheridan play transderm patch
deliveri vitamin supplement consum base formul
europ nutriband move oper unit state
recent acquisit inc shift emerg play
roll-out transderm patch product key medic use global
transderm supplement market burgeon pipelin abil
offer servic third part clinic develop
transderm drug deliveri market expect billion
grow annual rate level billion driver
expans includ continu shift current medic
transderm deliveri method increas demand transderm treatment
user want take pain daili shot and/or problem
swallow pill desir purer even drug intak believ
transderm patch market remain key growth driver overal
deal take compani next level medic transderm patch
august compani acquir inc exchang total
consider million acquisit ad full pipelin new
transderm medic formul pharmaceut space see figur
third-parti clinic develop capabl screen phase trial
small batch manufactur manag believ third-parti clinic
develop capac break-even current potenti
drive higher overal result near term rx pipelin catalyst
defent first major transderm patch medic offer tap
compani crown jewel deal defent patent pend
fentanyl transderm patch combin fentanyl blistex bitter
substanc known capsaicin activ ingredi pepper spray creat
first patent pend abus deterr patch fentanyl use believ given
continu opioid crisi need abus deterr fentanyl product
defent abil fda approv immedi materi
impact billion fentanyl patch market manag estim
eighteen-month trial period approxim cost million achiev fda
approv given defent reliant new drug product formul
obviou materi need product technolog
alreadi proven confid fda approv defent
approv drug facilit abus deterr patch opioid
sufentanil sold dsuvia sufenta antidepress
bupropion wellbutrin methylphenid adhd ritalin
could begin test roll-out defent conserv
assum revenu abus deterr patch except defent
type diabet patch next potenti medic blockbust next
gener transderm patch abl util larger water-solubl
molecul oppos smaller fat-solubl molecul materi expand
transderm medic market nutriband first plan product
categori exenatid type diabet sold byetta
bydureon brand offer benefit needl improv glucos
flow follicl stimul hormon fsh infertil manag
estim type diabet transderm patch fsh would cost approxim
million requir three-year period fda approv project
initi begin releas defent
septemb nutriband announc agreement acquir carmel
bioscienc inc carmel approxim million acquisit
complet would provid pipelin liquid reformul key drug
nutrit supplement fda approv right prexxartan
fda oral liquid dosag angiotensin receptor blocker valsartan
use treat hypertens carmel alreadi licens drug lead
biopharmaceut compani believ acquisit complet
immedi accret add anoth key dose technolog liquid
nutriband mix conserv wait transact close
expect earli updat financi project
stay true origin mission nutriband found offer
consum transderm patch vitamin supplement compani
alreadi creat numer formul key consum applic
energi vitamin sleep detox among other april nutriband
sign transderm consum product line distribut agreement
best choic inc korean consum product distributor agreement
exclus cover south korea republ china taiwan south asia
countri minimum first year order level million
contractu increas annual total valu deal minimum
million manag believ potenti sign master
distribut deal world-wide expect revenu best choic begin
recogn conserv assum
distribut agreement expans beyond current two twelv
design formul best choic licens limit revenu beyond
impress manag team given compani limit oper histori
first quarter product revenu nutriband solid
manag team key entrepreneuri scientif talent
bolster addit manag
increas capitalwithout increas float compani current
share count includ million share subject lawsuit
nutriband advanc brand inc advanc cancel
acquisit target compani success lawsuit recov
share next major hear decemb
believ nutriband capit complet test defent
believ manag want roll-out formul quicker exenatid
type diabet replac opioid deterr patch nutriband would
need addit capit million ntrb share advanc
return nutriband could potenti rais addit capit secondari
offer depend offer size still reduc overal share count
project impact pend lawsuit increment capit
view project ep
respect pragmat possibl conserv
compani fiscal year end januari assum incom
sourc outsid best choic distribut agreement third parti
servic driver assum minim
revenu level oper margin manag expect note
compani alreadi announc accret acquisit carmel
incorpor acquisit project complet
project nutriband begin regist sale
project approxim nine month defent driven revenu
market share approxim overal fentanyl patch market
oper margin manag expect assum
million increas account product support ramp-up
obvious project hing time defent approv roll-out
approv delay cancel impact nutriband would
near critic point nutriband initi coverag ntrb
buy rate price target manag labor multipl shift
busi model alway focu transderm patch
opportun acquisit potenti close
carmel deal nutriband manag creat medic dose altern play
believ offer materi overal return high level visibl
investor recent distribut agreement consum transderm
patch applic best choic asia profit harbing
global expans consum side believ compani
move forward multipl front roll-out defent major loom
posit price target translat ep util
annual discount rate given uncertainti approv defent view
valuat correct note defent achiev key mileston discount
declin view ntrb suitabl conserv investor
believ risk/reward especi given view realist
initi coverag ntrb buy rate price target
initi coverag
nutriband emerg drug
deliveri compani emphasi transderm patch technolog buy
rate price target januari ep discount
annual rate believ roll-out defent abus deterr
patch technolog deliveri fentanyl grow consum
third parti servic platform near term longer term
transderm patch solut medicin deliveri type diabet
opioid follicl simul hormon key ailment nutriband
aris leader transderm patch space recent announc
acquisit liquid drug deliveri system player carmel bioscienc inc
view project strike pragmat balanc product driven
compani assum new drug rollout besid defent aggress
postur term fund new rx product incorpor potenti
accret carmel bioscienc acquisit project oper margin
manag confid achiev assum
compani switch full tax payer current share count
ntrb share dilut share outstand overal share
count said project roll-out defent fda
approv defent captur immedi materi approxim
market share believ creat conserv case
incorpor fda approv time roll-out defent guarante
drug launch time market share gain project
recommend ntrb conserv investor said believ
risk/reward appropri initi coverag ntrb buy rate
found april adjunct thesi busi
manag student dublin institut technolog entrepreneur
entrepreneur year nutriband origin envis transderm
provid vitamin supplement consum europ januari
compani transfer manufactur oper unit state
largest marker transderm patch
next key step nutriband expans transderm rx space
via acquisit inc august million
cash share ntrb offer full pipelin
emerg transderm rx product figur includ defent abus
deterr technolog fentanyl transderm exenatid type diabet
also oper third parti clinic manufactur servic busi
septemb nutriband announc agreement acquir carmel
bioscienc inc million share ntrb stock impli
valuat per share carmel focus oral liquid technolog carmel
receiv fda approv decemb prexxartan first approv oral
liquid version valsartan hypertens carmel also four product
pipelin right nutrit supplement
coupl recent distribut agreement best choic
inc market nutriband origin consum supplement key asian market
nutriband cusp emerg key transderm believ
transderm technolog emerg growth arena rx space
marketsandmarket com estim transderm drug deliveri market
expect billion grow annual rate
level billion transderm market exist sinc ancient
time chines doctor put medic plaster patient left
dri fda approv first transderm patch motion
sick fda current classifi transderm patch combin
devic medic devic combin drug biolog deliv
transderm patch need receiv approv fda
releas believ numer reason transderm market
outgrow overal rx market
easier take transderm patch elimin need pain shot
provid materi comfort mean dosag mani
patient find swallow pill pain addit patch replac
need multipl daili dose easili forgotten
exampl type diabet user take two shot per day versu singl
directli bloodstream oppos filter liver
medic deliv via transderm patch activ
minut versu hour pill deliveri medic
activ user bodi heat
even dose benefit medicin deliv transderm patch deliv
even fashion transderm patch leverag permeabl
skin deliv even dose oppos singl pill
bypass stomach pill digest acid digest
system lead limit effect medic
potenti harm side effect
entir medic oppos pill util filler
flavor dosag
sum transderm medicin deliveri safer easier less invas
make compel deliveri method user
acquisit patient payer
provid physician
million cash share ntrb offer
materi posit nutriband immedi term provid compani
profit leverag revenu stream third parti pre-clin
phase manufactur servic longer term importantli
offer full pipelin transderm rx product includ defent abus
deterr technolog fentanyl opioid emerg novel
transderm peptid protein solut type diabet follicl
third parti testinga key near term posit excit
investor longer term believ third parti servic key posit
servic focus complet depend
preclin feasibl assess abil compound
effect deliv via particular drug deliveri technolog conduct
test determin optim formul drug deliveri configur
initi clinic test
chemistri manufactur control develop
develop small-scal manufactur process product qualiti
control allow begin phase fda test
manufactur capabl manufactur transderm patch
solut test fda approv shift larger
scale manufactur fda current manufactur process
regulatori affair experi capabl creat
fda investig new drug ind applic track process
amend mainten correspond fda
clinic research perform clinic research util fda
clinic practic ich intern council harmonis
technic requir pharmaceut human use guidelin
abil complet overse phase test act support
team player
qualiti assur fulli vers code feder regul
pertain design develop test manufactur
clinic test devic drug biolog combin product
sum abil shepherd drug creation process effect
effici manner begin phase i/ii test emphasi
transderm technolog parti increasingli
busi parti busi remain solid revenu driver
year-end decemb decemb respect
overal oper margin busi year-end decemb
impress manag believ remain materi top
oper margin opportun parti busi compani
expand effort drive growth note revenu
acquir nutriband yoy project continu top
line growth segment maintain oper margin assum
limit leverag highli fix cost busi
defentth first potenti rx blockbust nutriband
third-parti servic provid stream cash flow repres
opportun key driver transact pipelin
first major plan product defent fentanyl abus deterr transderm
fentanyl abus becom materi part overal opioid epidem
drug oxycodon switch deterr driven regim abus
potent time potent morphin fentanyl
continu rise accord jama synthet opioid primarili
illeg fentanyl pass prescript drug common drug involv
overdos death unit state fold
increas death synthet opioid
nation center health statist cdc wonder
key issu fentanyl abil addict abus fentanyl transderm
patch continu addict creativ off-label use patch
includ multipl fentanyl patch use directli inject narcot gel
fentanyl patch boil fentanyl patch creat tea chew smoke
snort fentanyl patch among other short limit deterr
current fentanyl patch market
said transderm patch among safest easiest way patient
sever pain use drug usag period hour
nutriband manag estim domest market fentanyl transderm
patch approxim billion fentanyl pill market three four
nutriband defent domest patent pend product recent
receiv intent grant notic european patent offic creat
abus deterr ad addit layer transderm patch coat
denatonium benzoat capsaicin
denatonium benzoat bitrex accord guin book world
record bitterest substanc known man drop thimbl full
bitrex olymp size swim pool million liter water
make water pool tast bitter said besid bitter bitrex
harmless make ideal product manufactur poison household
product use bitrex prevent accident human consumpt primarili
children toddler
capsaicin activ compon chili pepper activ ingredi
riot control person defens pepper spray agent addit
ingredi fentanyl patch serv deter destruct
alter patch non-leg purpos note tradit user
transderm fentanyl patch addit defent deterr ingredi
impact
believ defent transderm patch eleg method curtail usag
fentanyl patch non-prescrib use manag believ fda
approv process take eighteen month cost
approxim million number factor give us
confid detent approv
new formul defent chang formul
ingredi key test fda approv human abus
liabil studi track user reaction patch
abil control process nutriband abl conduct fda
approv process via divis alreadi provid third parti
altern transderm fentanyl market histor fentanyl
patch manufactur tri chang overal formul patch
prevent abus unfortun chang led materi side effect
expect issu defent
product desper need deterr abus system
remain materi legitim use fentanyl especi cancer patient
undergo treatment materi pain treat
opioid recogn need fda safe solut
nutriband manag expect rapid market accept defent
fda approv compani envis manufactur product
aegi roll help line sale forc given
risk/reward reduc lawsuit overal overdos risk expect defent
compel choic hospit payer doctor note plan
defent price level similar fentanyl patch
project roll-out product initi roll-out
million overal gross margin believ increas
nutriband leverag emerg infrastructur revenu project
assum compani captur approxim overal fentanyl
final note abil leverag fda approv process defent
opioid
treatment morphin methadon sufentanil
antidepress buproprion adhd treatment methylphenid
conserv assum increment revenu abus
expand transderm patch market peptid protein via
although transderm patch offer materi advantag pill inject
limit permeabl skin restrict abil util patch
larger molecul current major transderm patch util
smaller molecul medicin besid fentanyl transderm treatment
includ nicotin largest patch market opioid buprenorphin market
butran hormon patch estrogen testosteron birth control
manag believ novelti non-smal molecul transderm patch
market repres materi opportun market protein/peptid
offer billion
compani first key novel transderm patch candid exenatid key
peptid driven diabet type treatment taken inject twice day
abdomen thigh arm type diabet major lifestyl diseas
unit state accord center diseas control prevent
cdc million american diabet million
exhibit pre-diabet symptom cost treat type diabet remain
high cdc estim annual medic cost billion billion
transderm patch exenatid would repres major posit user
elimin pain inconveni take two inject day
eat allow much smoother drug flow day oppos
two major inject allow better glucos control
reduc risk missed/forgotten dose
nutriband alreadi demonstr feasibl data human manag
project cost approxim million three year
version exenatid approv use fda project
revenu novel transderm exenatid patch project
manag also believ technolog novel transderm
patch follicl simul hormon fsh protein infertil
transderm patch would replac subcutan inject improv
potenti success vitro fertil also opportun
longer term novel transderm patch scopolamin lidocain
project revenu novel transderm patch
carmel bioscienc acquisit step becom dose
agreement purchas carmel bioscienc inc
approxim million restrict share
carmel focus
reformul key drug creat new chemic entiti focus oral
deliveri system acquisit includ fda approv prexxartan
carmel pipelin new drug
prexxartan approv fda decemb first
domest approv oral liquid dosag valsartan angiotensin receptor
blocker util treatment hypertens adult children six
year old off-pat sinc septemb valsartan well-establish drug
medicur inc
right market distribut prexxartan exclus unit state
biopharmaceut compani headquart winnipeg manitoba focus
cardiovascular treatment revenu last twelv month end june
approxim million seven-year licens agreement cover
octob
mileston payment certain revenu level licens fee base
prexxartan key posit nutriband near term financi
result estim initi licens fee million first year
nutriband ownership importantli carmel posit compani
transderm patch player emerg dose altern
incorpor carmel project said expect
acquisit close project base first year licens
revenu million margin rate acquisit carmel
could accret depend time close
acquisit
creat intern consum transderm patch busi
given need fda approv transderm patch creat domest
franchis offer supplement driven consum transderm patch somewhat
problemat expens estim cost least million per
formul said thrive intern busi consum
transderm patch offer user daili vitamin energi boost sleep
enhanc treatment
may nutriband sign exclus million distribut
agreement best choic inc korea line consum transderm
patch best choic twenty-year histori distribut product key
retail costco lott depart store locat south
korea initi product offer nutriband energi vitamin
patch formul readi introduc amino acid slimlin
nausea motion sick glucosamin detox
agreement cover south korea taiwan peopl republ china
south asia countri initi order volum million increas
annual initi order deliv
south korean market initi focu manag
believ new formul introduc best choic expand beyond
south korea drive revenu beyond contractu guarante
compani convers potenti distributor
estim assum distribut agreement beyond best choic
pact project order near minimum contractu guarante level
project gross margin consum transderm patch sale
nutriband near revenu attain impress acquisit
drug pipelin compani abl retain highli experienc deep
gareth sheridan chief execut offic gareth sheridan award-
win entrepreneur businessman founder nutriband inc mr
sheridan ireland young entrepreneur year
establish nutriband ltd nutriband award ireland
best new product mr sheridan busi award
dublin best young entrepreneur dublin best start-up compani
mr sheridan also work busi mentor mind social
enterpris found bring togeth ireland top colleg
student connect one caus achiev larg charit goal
short space time mr sheridan also past nissan gener
ambassador receiv acknowledg nissan ireland
one ireland futur gener leader mr sheridan receiv sc
busi manag dublin institut technolog
concentr intern econom ventur creation
serguei melnik chief financi offic mr melnik involv
gener busi consult compani financi market
set legal financi framework oper foreign compani
 mr melnik advis unr hold inc regard
initi trade stock over-the-count market
 provid gener advic respect financi
market compani locat abroad februari
may chief oper offic board member
asconi corpor winter park florida regard restructur
compani list american stock exchang mr melnik
june decemb lawyer depart foreign
affair jsc bank inteprinzbanca chisinau moldova prior thereto
practic law moldova variou posit mr melnik fluent
russian romanian english spanish
sean gallagh presid sean gallagh experienc businessman
inspir speaker highli regard busi writer also stood
independ candid runner irish presidenti
elect sean notabl busi ventur includ co found serv
ceo clyde estat pharmaceut directorship co-found
ireland largest home technolog compani smarthom sean also
serv investor popular tv show dragon den ireland
uk version popular us tv show shark tank sean qualifi
mba univers ulster previous work one
ireland enterpris agenc past year train
mentor hundr emerg entrepreneur also serv
number irish state board includ nation train
employ agenc fa north south trade bodi intertrad
ireland chair state-own drogheda port compani
director drug develop institut ohio state univers
comprehens cancer center dr patrick recent serv chief
scientif offic new prior role includ
global vice presid profession affair mallinckrodt pharmaceut
inc role ascend respons dyax myogen/gilead
actelion sanofi-synthelabo inc dr patrick residency-train
clinic pharmacist approxim year pharmaceut industri
experi bring expertis execut leadership scientif
medic strategi drug develop commerci compani
prior pursu career research develop patrick
ambulatori care clinic pharmacist univers tennesse medic
center clinic assist professor pharmaci univers
tennesse colleg pharmaci earn doctor pharmaci
also complet wharton school busi pharmaceut
alan smith ph head clinic regulatori qualiti oper
alan smith ph co-found serv vice
presid clinic regulatori qualiti oper previous
altea therapeut recent serv vice presid product
develop head clinic regulatori affair project
manag altea led major research develop program
pharmaceut compani amylin hospira
novarti join altea one first employe spent year
grow multidisciplinari drug deliveri research develop
organ dr smith year experi research
develop drug biolog deliveri system diagnost medic
devic treatment manag diabet chronic pain
cardiovascular diseas prior join altea therapeut led
develop transderm glucos monitor system spectrx inc
degre biomed engin rutger univers
univers medicin dentistri new jersey current serv
editori advisori board expert opinion drug deliveri
hidden asset potenti capit higher return
project envis capit rais necessari defent
approv fda compani decid aggress pursu
transderm patch rx type diabet opioid treatment
project necessari work capit defent approv roll
said potenti hidden asset could eventu util
manag add capit dilut current sharehold base
may nutriband acquir advanc health brand inc five million
ntrb share expect advanc health would serv
platform nutriband transderm rx expans said acquisit
emerg origin project nutriband manag juli
nutriband board vote rescind acquisit engag council
recov ntrb share next rule case schedul
decemb nutriband recov million ntrb share
includ current share count option reissu share
rais expans capit and/or reduc overal share count note
million secondari offer could allow earlier initi test
novel transderm patch test type diabet exenatid expans
defent beyond fentanyl opioid
view project pragmat base case
alreadi broken top line project
product line level result revenu million
million sale million impact revenu
project includ start best choic contract
continu contractu guarante ramp materi growth
parti test servic nutriband manag expand level
offer increas market effort add new physic space
launch defent captur approxim market
share fentanyl patch market assum acquisit
revenu project includ alreadi announc carmel bioscienc deal
new distributorship consum transderm patch new
term gross margin product mix key driver project gross
margin parti servic consum transderm patch
defent oper margin project layer limit
cost parti servic consum transderm product primarili due
low gross margin assumpt parti servic also
incorpor vast major parti expens distribut
arrang consum transderm patch partner best choic
increment shift incorpor million develop
cost spread million infrastructur cost
includ cost hotlin hire sale
repres cost self-manufactur support roll-out
project loss per share
ep defent debut also project
tax rate even though expect compani
net oper loss credit enter fiscal year end
nutriband nol approxim million
near critic point nutriband initi coverag ntrb
buy rate price target manag labor multipl shift
busi model alway focu expans
transderm patch acquisit therapeut
announc carmel bioscienc deal nutriband creat medic
dose altern play believ offer materi overal return
high level visibl investor recent distribut agreement
consum transderm patch applic best choic asia
profit harbing global expans consum side
believ compani move forward multipl front roll-out
defent major loom posit price target translat
ep util annual discount rate given uncertainti
approv defent view valuat correct given stage
compani view ntrb suitabl conserv investor
believ risk/reward especi given conserv project merit
valuat price target ntrb translat ep
discount rate due uncertainti associ time
size launch compani defent fentanyl patch product
risk buy rate price target ntrb includ
compani materi growth driver defent approv use
fda transderm patch market remain highli fragment nutriband
compet player materi larger size financi resourc
compani fulli financ plan product rollout invest
earli stage medic compani entail high level risk view ntrb
suitabl invest conserv investor
small cap consum research llcnutriband statement fye except per share consum transderm patches/best choice- parti servic defent- total revenue- good sold- gross margin- expens non-cash compensation- intang impair charge- oper incom incom taxes- net earn loss per dilut share margin analysisgross incom analysi revenu incom yoynmnmnmnmnmnmnmnmnmep yoynmnmnmnmnmnmnmnmnmsourc compani report small cap consum research llc nutriband inc
small cap consum research llcnutriband sheet fye except per share asset equival prepaid vat current properti equip deposit acquisit liabil account payabl accru defer due relat note current equiti common addit retain stockhold liabil stockhold sourc compani report small cap consum research llc nutriband inc
small cap consum research llcnutriband fye except per share net incom reconcil net incom loss expens paid co relat amort stock base oper asset liabil prepaid account payabl accru defer provid oper paid acquisit use invest proce repay relat proce st proce net stock financ exchang rate chang increas decreas begin end total end compani report small cap consum research llc nutriband inc
eric beder certifi view express includ limit price target rate financi estim herein accur reflect person view
secur compani compani mention report
valuat price target ntrb translat ep discount rate due uncertainti associ time size
launch compani defent fentanyl patch product
risk buy rate price target ntrb includ compani materi growth driver defent approv fda transderm
patch market remain highli fragment nutriband compet player amteri larger size financi resourc compani fulli financ
plan product rollout invest earli stage medic compani entail high level risk view ntrb suitabl invest conserv
rate distribut percentag invest bank disclosur chart inform
